[go: up one dir, main page]

WO2010132547A3 - Oxaza heterocyclic compounds for phototherapy - Google Patents

Oxaza heterocyclic compounds for phototherapy Download PDF

Info

Publication number
WO2010132547A3
WO2010132547A3 PCT/US2010/034512 US2010034512W WO2010132547A3 WO 2010132547 A3 WO2010132547 A3 WO 2010132547A3 US 2010034512 W US2010034512 W US 2010034512W WO 2010132547 A3 WO2010132547 A3 WO 2010132547A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxaza
compounds
phototherapy
photolabile
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/034512
Other languages
French (fr)
Other versions
WO2010132547A2 (en
Inventor
Raghavan Rajagopalan
Amruta Poreddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Publication of WO2010132547A2 publication Critical patent/WO2010132547A2/en
Publication of WO2010132547A3 publication Critical patent/WO2010132547A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates generally to optical agents, including phototherapeutic agents, for biomedical applications, including phototherapy. The invention includes optical agents, and related therapeutic methods, comprising oxaza compounds, including 1,2 oxaza heterocyclic compounds, having a photolabile N-O bond directly or indirectly linked to at least one carbocyclic aromatic and/or heterocyclic aromatic group. In some embodiments, for example, the invention provides oxaza compounds, such as oxazolines and isoxazolidines, for phototherapeutic methods having a photolabile N-O bond that undergoes photoactivated cleavage to produce reactive species, such as radicals, ions, etc., that achieve a desired therapeutic effect, such as selective and/or localized tissue damage and/or cell death.
PCT/US2010/034512 2009-05-12 2010-05-12 Oxaza heterocyclic compounds for phototherapy Ceased WO2010132547A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17733709P 2009-05-12 2009-05-12
US61/177,337 2009-05-12
US28693309P 2009-12-16 2009-12-16
US61/286,933 2009-12-16

Publications (2)

Publication Number Publication Date
WO2010132547A2 WO2010132547A2 (en) 2010-11-18
WO2010132547A3 true WO2010132547A3 (en) 2011-01-13

Family

ID=42790953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/034512 Ceased WO2010132547A2 (en) 2009-05-12 2010-05-12 Oxaza heterocyclic compounds for phototherapy

Country Status (1)

Country Link
WO (1) WO2010132547A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010132515A1 (en) 2009-05-12 2010-11-18 Mallinckrodt Inc. Compounds containing acyclic n-n bonds for phototherapy
US9186349B2 (en) 2009-05-12 2015-11-17 Mallinckrodt Llc Diaza heterocyclic compounds for phototherapy
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035536A2 (en) * 2002-10-15 2004-04-29 Mallinckrodt Inc. Azo compounds for type i phototherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035536A2 (en) * 2002-10-15 2004-04-29 Mallinckrodt Inc. Azo compounds for type i phototherapy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AMOLKUMAR KARWA ET AL: "In vitro biological effects of novel type 1 photosensitizers and their mechanism of action", PROCEEDINGS OF THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING (SPIE); 20100123, vol. 7551, 23 January 2010 (2010-01-23), pages 75510S/1 - 7, XP009140794, ISSN: 0277-786X, [retrieved on 20100302] *
LIU X ET AL: "Synthesis of novel isoxazole-fused chlorins and bacteriochlorins via 1,3-dipolar cycloaddition reactions of nitrile oxides with porphyrins", SYNTHESIS 20051220 GEORG THIEME VERLAG DE, no. 20, 20 December 2005 (2005-12-20), pages 3632 - 3638, XP002608537, DOI: DOI:10.1055/S-2005-918415 *
PRIYA B S ET AL: "DELTA.2-Isoxazoline derivatives as antimicrobials", HETEROCYCLIC COMMUNICATIONS, FREUND PUBLISHING HOUSE, TEL AVIV, vol. 12, no. 1, 1 January 2006 (2006-01-01), pages 35 - 42, XP009140872, ISSN: 0793-0283 *
RAGHAVAN RAJAGOPALAN ET AL: "Novel type 1 photosensitizers: viability of leukemia cells exposed to reactive intermediates generated in situ by in vitro photofragmentation", PROCEEDINGS OF THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING (SPIE); 20090611, vol. 7380, 11 June 2009 (2009-06-11), pages 738027/1 - 8, XP009140796, ISSN: 0277-786X, [retrieved on 20090713] *
RAGHAVAN RAJAGOPALAN ET AL: "Novel visible light activated type 1 photosensitizers", PROCEEDINGS OF THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING (SPIE); 20100123, vol. 7551, 23 January 2010 (2010-01-23), pages 7551R/1 - 6, XP009140795, ISSN: 0277-786X, [retrieved on 20100302] *
TOSHIO MUKAI, TSUTOMU KUMAGAL, HIROSHI SAIKI, YASUHIKO KAWAMURA: "Photochemical behaviour of cyclic imino ethers: The N---O bond fission,syn-anti isomerization and cycloaddition reactions in the C=N---O chomophore", JOURNAL OF PHOTOCHEMISTRY, vol. 17, no. 2, 1 January 1981 (1981-01-01), pages 365 - 368, XP009140894, DOI: 10.1016/0047-2670(81)85378-6 *

Also Published As

Publication number Publication date
WO2010132547A2 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
WO2008124675A3 (en) Methods of controlling algae with thaxtomin and thaxtomin compositions
WO2008011453A3 (en) SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
NZ580016A (en) Protective mask with countering of microorganisms with fluid which may include other microorganisms
PT1938839E (en) Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia
ECSP13013035A (en) COMBINATIONS OF ACTIVE COMPOUNDS THAT INCLUDE A DERIVATIVE OF (UNCLE) CARBOXAMIDE AND A FUNGIED COMPOUND
CR11383A (en) PIRIDIN-2-IL-AMINO-1,2,4 -TIADIAZOL DERIVATIVES AS GLUCOQUINASE ACTIVATORS FOR THE TREATMENT OF MELLITUS DIABETES
SI2176252T1 (en) 2, 3-dihydrobenzoš1, 4ćdioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases
WO2010036395A3 (en) Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
WO2006030439A3 (en) Compositions and methods for inducing hair growth
PH12019501469A1 (en) Compositions and methods for treating biofilms
WO2009133374A3 (en) Antisapstain compositions comprising a haloalkynyl compound, an azole and an unsaturated acid
GB2442915B (en) Perylenequinone derivatives and uses thereof
EA201100874A1 (en) COMPOUNDS FOR CANCER TREATMENT
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
WO2010032011A3 (en) Anti-fungal therapy
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
PT2056804E (en) USE OF 2,5-DIHYDROXYBENZEN DERIVATIVES FOR THE TREATMENT OF EYE DISEASES
ATE538799T1 (en) COMPOSITIONS FOR TREATING HAIR LOSS
WO2010074936A3 (en) Enzastaurin for the treatment of cancer
WO2011103276A3 (en) Abdominal wall treatment devices
PL1919466T3 (en) Formulations for treatment of lipoprotein abnormalities comprising a statin and a methylnicotinamide derivative
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2007081878A8 (en) Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2010132547A3 (en) Oxaza heterocyclic compounds for phototherapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10719509

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10719509

Country of ref document: EP

Kind code of ref document: A2